Cresset Asset Management’s Corcept Therapeutics CORT Stock Holding History

Cresset Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Sell	2,848 -11,696	-80%	-$706K	﹤0.01%	1483
2026 Q1	$586K	Sell	14,544 -248	-2%	-$9.27K	﹤0.01%	993
2025 Q4	$515K	Buy	14,792 +839	+6%	+$65.9K	﹤0.01%	1056
2025 Q3	$1.16M	Sell	13,953 -1,064	-7%	-$77K	0.01%	694
2025 Q2	$1.1M	Sell	15,017 -77,788	-84%	-$5.64M	0.01%	659
2025 Q1	$10.6M	Sell	92,805 -7,170	-7%	-$436K	0.05%	215
2024 Q4	$5.04M	Buy	99,975 +18,865	+23%	+$988K	0.02%	350
2024 Q3	$3.75M	Buy	81,110 +2,941	+4%	+$105K	0.01%	533
2024 Q2	$2.54M	Buy	78,169 +8,079	+12%	+$221K	0.01%	619
2024 Q1	$1.77M	Buy	+70,090	New	+$1.66M	0.01%	707
2019 Q2	–	Sell	-159	Closed	-$2K	–	716
2019 Q1	$2K	Sell	159 -19	-11%	-$236	﹤0.01%	1621
2018 Q4	$2K	Buy	+178	New	+$2.35K	﹤0.01%	1284

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's CORT Position: Q2 2026 in Review

Cresset Asset Management reduced its Corcept Therapeutics (CORT) stake by 80% in Q2 2026, selling an estimated $706K and leaving 2,848 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

Cresset Asset Management first reported a position in CORT in Q4 2018 and has held it in 12 quarters since. The position peaked at $10.6M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Cresset Asset Management held 2,848 shares of Corcept Therapeutics worth $248K as of Q2 2026.
Cresset Asset Management sold 11,696 Corcept Therapeutics shares in Q2 2026, an estimated $706K.
Corcept Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1483 holding.
Cresset Asset Management first reported a position in Corcept Therapeutics in Q4 2018 and has held it in 12 quarters since.
Cresset Asset Management's Corcept Therapeutics position peaked at $10.6M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.